Exelixis, Inc. (NASDAQ:EXEL) announced the initiation of a phase 1 trial of cabozantinib in combination with nivolumab alone or in combination with nivolumab plus …
Exelixis, Inc. (NASDAQ:EXEL)’s partner Genentech, a member of the Roche Group, informedExelixis that, in order to accommodate its review of a supplemental data …
Exelixis, Inc. (NASDAQ:EXEL) announced updated positive results for cobimetinib, an Exelixis-discovered investigational compound, in combination with vemurafenib for the treatment of patients with previously …
Exelixis, Inc. (NASDAQ:EXEL) announced that the U.
Cowen’s healthcare analyst Eric Schmidt weighed in today with his thoughts on Exelixis, Inc. (NASDAQ:EXEL), after the company reported its fourth-quarter results and business update.
Exelixis, Inc. (NASDAQ:EXEL) today reported financial results for the fourth quarter and full year of 2014 and provided an update on progress toward …
(BUSINESS WIRE)–Jan. 29, 2015– Exelixis, Inc.
In a research report issued yesterday, William Blair analyst John Sonnier maintained an Outperform rating on Exelixis (NASDAQ:EXEL). No price target provided.
In a research report released yesterday, William Blair analyst John Sonnier reiterated an Outperform rating on Exelixis Inc (EXEL). The report follows yesterday’s news of positive …
